499
Participants
Start Date
May 31, 2005
Primary Completion Date
November 30, 2007
Study Completion Date
November 30, 2007
Methotrexate
10-25mg weekly
Placebo
iv every 4 weeks
tocilizumab [RoActemra/Actemra]
8mg/kg iv every 4 weeks
tocilizumab [RoActemra/Actemra]
4mg/kg iv every 4 weeks
Reykjavik
Lausanne
Sydney
Merksem
Malvern
Hasselt
Woolloongabba
Shenton Park
Aalst
New York
New York
Berlin
Great Neck
Albany
Johnson City
Binghamton
Orchard Park
Rochester
Duncansville
Danville
Bala-Cynwyd
Philadelphia
Philadelphia
Milan
Milan
Wheaton
Baltimore
Baltimore
Richmond
Norfolk
Salem
Brescia
Pavia
Charlotte
Wilmington
Hickory Grove
Asheville
Atlanta
Toulouse
Tavares
Bordeaux
Udine
Aventura
Fort Lauderdale
West Palm Beach
Boca Raton
Zephyrhills
Tampa
Sarasota
Palm Habor
Padua
Birmingham
Huntsville
Jackson
Tupelo
Gommern
Louisville
Lexington
Bowling Green
Elizabethtown
Guadalajara
Herne
Canton
Cincinnati
Lansing
Cologne
Glendale
Duluth
Rochester
Pisa
Bismarck
Lille
Missoula
Chicago
Springfield
Springfield
St Louis
St Louis
St Louis
St Louis
Karlstad
Wiesbaden
Strasbourg
Lyon
New Orleans
Hot Springs
Little Rock
Oklahoma City
Tulsa
Tulsa
Dallas
Paris
Paris
Houston
Austin
Willow Grove
Amiens
Colorado Springs
München
Meridian
Boise
Ogden
Scottsdale
Scottsdale
Tucson
Las Vegas
Los Angeles
Torrance
Long Beach
Long Beach
San Diego
San Diego
Palm Desert
Anaheim
Fullerton
Santa Maria
Le Kremlin-Bicêtre
Würzburg
Eugene
Seattle
Seattle
Indianapolis
Portland
Springfield
Worcester
Billings
Medford
Mercerville
Teaneck
Chapel Hill
Dallas
Calgary
Edmonton
Winnipeg
Burlington
Kitchener
London
Mississauga
Newmarket
Toronto
Montreal
Nice
Dresden
Enschede
Nijmegen
Ponce
Jönköping
Malmo
Stockholm
Basingstoke
Bath
Birmingham
Cannock
Derby
Lancaster
Leeds
Liverpool
London
London
Manchester
Manchester
Middlesbrough
Newcastle upon Tyne
Norwich
Oxford
Salford
Southampton
Stoke-on-Trent
Hoffmann-La Roche
INDUSTRY